Related Experiment Video
Updated: Jun 5, 2025
Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
Published on: July 5, 2018
Structural insight into CD20/CD3-bispecific antibodies by molecular modeling
Ze-Yu Sun1, Tianjian Liang1, Yiyang Zhang1
1Department of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, and Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy, National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, PA 15261, United States.
This study improved a computational method to analyze how bispecific T cell engagers (TCEs) bind to CD3 targets. This enhances understanding of antibody interactions for better immunotherapy design against Non-Hodgkin's Lymphoma.
Area of Science:
- Hematology
- Immunology
- Computational Biology
Background:
- Non-Hodgkin's Lymphoma (NHL) treatment faces challenges with conventional therapies.
- Bispecific T cell engagers (TCEs) show promise in immunotherapy but have associated adverse events.
- Understanding structural interactions of TCEs with target proteins is vital for optimizing efficacy and safety.
Purpose of the Study:
- To refine the MCCS-Docker protocol for analyzing protein-protein interactions.
- To investigate the structural details of CD3 interactions with various therapeutic antibodies.
- To identify key residues involved in the binding interface of TCEs with CD3.
Main Methods:
- Utilized an updated MCCS-Docker protocol for computational modeling.
- Performed docking studies to predict binding poses of antibodies to CD3.
- Conducted molecular dynamics simulations to validate interaction stability.
Main Results:
- Validated the effectiveness of the updated MCCS-Docker protocol.
- Revealed detailed binding interactions between specific bispecific antibodies and CD3.
- Identified key Tyrosine and Asparagine residues in antibodies critical for CD3 binding.
Conclusions:
- The study provides a novel method for predicting critical residues in protein-protein interactions.
- Enhanced understanding of structural determinants governing TCE-CD3 interactions.
- Offers insights for designing improved immunotherapeutic agents for hematologic malignancies like NHL.
